BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38490370)

  • 1. Risk of systemic lymphoma in patients with cutaneous CD30+ lymphoproliferative disorders: A single center retrospective cohort analysis.
    Chen J; Martinez A; Shinohara MM
    J Am Acad Dermatol; 2024 Jul; 91(1):134-135. PubMed ID: 38490370
    [No Abstract]   [Full Text] [Related]  

  • 2. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
    Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
    Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
    Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.
    Sanka RK; Eagle RC; Wojno TH; Neufeld KR; Grossniklaus HE
    Ophthalmology; 2010 Feb; 117(2):343-51. PubMed ID: 19969358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
    Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
    J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SATB1 Defines a Subtype of Cutaneous CD30
    Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
    J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
    Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
    Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
    Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
    Wood GS; Hardman DL; Boni R; Dummer R; Kim YH; Smoller BR; Takeshita M; Kikuchi M; Burg G
    Blood; 1996 Sep; 88(5):1765-70. PubMed ID: 8781433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
    Wada DA; Law ME; Hsi ED; Dicaudo DJ; Ma L; Lim MS; Souza Ad; Comfere NI; Weenig RH; Macon WR; Erickson LA; Ozsan N; Ansell SM; Dogan A; Feldman AL
    Mod Pathol; 2011 Apr; 24(4):596-605. PubMed ID: 21169992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
    Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
    Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat primary cutaneous CD30
    Shinohara MM; Shustov A
    Blood; 2019 Aug; 134(6):515-524. PubMed ID: 31164331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
    Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
    J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the t(2;5) (p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
    Wood GS
    Leuk Lymphoma; 1998 Mar; 29(1-2):93-101. PubMed ID: 9638979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
    Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
    Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
    Vonderheid EC; Sajjadian A; Kadin ME
    J Am Acad Dermatol; 1996 Mar; 34(3):470-81. PubMed ID: 8609262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.
    Bekkenk MW; Geelen FA; van Voorst Vader PC; Heule F; Geerts ML; van Vloten WA; Meijer CJ; Willemze R
    Blood; 2000 Jun; 95(12):3653-61. PubMed ID: 10845893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30+ T-cell lymphoproliferative disorders.
    Martin JM; Wu H; Barta SK
    Chin Clin Oncol; 2019 Feb; 8(1):4. PubMed ID: 30525751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30(Ki-1)-positive anaplastic large cell lymphoma.
    Tomaszewski MM; Lupton GP; Krishnan J; May DL
    J Cutan Pathol; 1995 Aug; 22(4):310-8. PubMed ID: 7499570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cutaneous anaplastic large cell lymphoma.
    Brown RA; Fernandez-Pol S; Kim J
    J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.